Skip to main content
(from left) Julia Nicke and Dr. Mona Malek Mohammadi have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury.
© University Hospital Bonn (UKB) / Alessandro Winkler

News categories: Publication

Central Hub for Heart Repair Discovered Bonn study: Heart muscle interaction enables cardiac regeneration in the neonatal heart

Researchers at the University Hospital of Bonn (UKB) and the University of Bonn have identified a previously unknown signaling pathway in the immune system that helps newborn heart cells survive and regenerate after injury. The findings could open new avenues for future therapies aimed at repairing damaged adult hearts after heart attacks or chronic cardiovascular disease. The study has now been published in the journal Cell Communication and Signaling (Springer Nature).

Unlike adult hearts, the hearts of newborn mammals can temporarily regenerate after damage. However, this remarkable ability is rapidly lost within the first days of life. In the new study, scientists investigated how neonatal hearts respond both to heart injury and to pressure overload, a condition that mimics chronic stress on the heart. 

Immune cells communicate via signaling pathways that function like a chain of dominoes. In this process, signaling molecules trigger the next signal until a reaction is initiated. In a neonatal mouse model, the research team discovered that three immune-related signaling molecules — CCL4, S100A8, and C1QA — work together to activate a receptor called TLR2 on heart muscle cells. Activation of this pathway stimulated heart cell proliferation, enhanced survival of heart muscle cells, and reduced cell death.

“Our findings reveal an unexpected communication axis between immune signals and heart muscle cells that supports regeneration in the neonatal heart,” said corresponding author Dr. Mona Malek Mohammadi, head of a research group at the Institute of Physiology I at the UKB and the University of Bonn. “We were particularly surprised to find that TLR2 acts as a central hub connecting inflammatory signals to regenerative responses.”

No signaling pathway—no heart repair

To validate the importance of TLR2, the researchers used genetically modified mice lacking the receptor. These mice were unable to adapt to cardiac stress and rapidly developed heart failure. “This shows that TLR2 is essential for maintaining protective and regenerative responses in the neonatal heart,” says the first author Julia Nicke.

Importantly, the study also showed that TLR2 expression is much higher in newborn heart cells than in adult heart cells, suggesting that loss of this signaling pathway may contribute to the poor regenerative capacity of the adult heart.

The researchers believe these findings may eventually help scientists develop therapies that reactivate neonatal-like repair mechanisms in adult hearts after myocardial infarction or heart failure. “Current cardiovascular therapies mainly slow disease progression,” said Dr. Malek Mohammadi. “Our long-term goal is to promote true cardiac repair and regeneration.”

 

Funding

The study was conducted at the UKB and funded by the German Society of Cardiology (Deutsche Gesellschaft für Kardiologie, DGK) through a research grant awarded to Dr. Mona Malek Mohammadi.

Publication

Julia Nicke, Adrian Goldspink, Malte Menn, Bernd K. Fleischmann, Mona Malek Mohammadi: TLR2 mediates cell cycle re-entry and survival of neonatal cardiomyocytes in response to injury; Cell Communication and Signaling (Springer Nature); DOI: https://doi.org/10.1186/s12964-026-03147-w 

Scientific contact:

Dr. Mona Malek Mohammadi
Institute of Physiology I
University Hospital Bonn and University of Bonn
Phone: +49 (0) 228 28762-216
Email: mona.malekmohammadi@uni-bonn.de 

Press contact

Dr. Inka Väth
Deputy Press Officer at the University Hospital Bonn (UKB)
Public Relations and Corporate Communication at UKB
Phone: (+49) 228 287-10596
E-mail: inka.vaeth@ukbonn.de 

Related news

News Icon

News categories: Publication

Malaria Causes Permanent Damage to Phagocytes in the Spleen

Macrophages formed in the bone marrow can only assume the function of embryonal phagocytes, or “scavenger cells,” to a certain degree according to a study by the University of Bonn and the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. The researchers have demonstrated that malaria infection causes permanent damage to resident CD163 macrophages in the spleen, which are responsible for cleaning the blood, recycling iron and communicating with other cells involved in the body’s immune response.
View entry
Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry

Back to the news overview